William Blair analyst Myles Minter has maintained their bullish stance on ALNY stock, giving a Buy rating on October 27.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Myles Minter has given his Buy rating due to a combination of factors, including Alnylam Pharma’s robust financial performance and strong sales growth in its TTR franchise. The company reported quarterly revenues that exceeded both the firm’s and market expectations, driven by a significant increase in sales of Amvuttra, which showed impressive growth in its second full quarter since launch.
Additionally, Alnylam’s upward revision of its total net product revenue guidance for 2025 reflects confidence in sustained growth, particularly in the ATTR-cardiomyopathy market. The narrowing of non-GAAP R&D and SG&A expenses further supports the company’s path towards profitability, making it an attractive investment opportunity. These elements combined underpin Minter’s Buy rating for Alnylam Pharma.
Minter covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals, Biogen, and Argenx Se. According to TipRanks, Minter has an average return of 30.1% and a 61.69% success rate on recommended stocks.
In another report released on October 27, Bernstein also maintained a Buy rating on the stock with a $471.00 price target.